



# Supplementary Figure S1



**Figure S1. <sup>89</sup>Zr-oxine labeling does not alter surface phenotype of NK cells.**

**A.** Expression of CD56 and CD16 on *ex vivo* expanded RM NK cells from 3 unrelated RMs was examined by flow cytometry up to 24 hours after labeling. Surface expression of these markers was not altered by <sup>89</sup>Zr-oxine labeling. **B.** The majority of *ex vivo* expanded <sup>89</sup>Zr-labeled and non-labeled RM NK cells remained NKG2A positive during the 24 hours post-labeling tested (n=3). **C.** Similarly, CD56 and CD16 expression of *ex vivo* expanded NK cells from 3 unrelated humans was not altered by <sup>89</sup>Zr-labeling (n=3).


## Supplementary Figure S2



**Figure S2. Quantitation of PET/CT images of adoptively transferred  $^{89}\text{Zr}$ -oxine-labeled NK cell reveals low BM homing.**

**A.** Kinetics of SUV values with magnified X-axis up to day 1. **B.** % ID curves with magnification of X-axis up to day 1 indicated rapid migration of the cells to the liver while homing to the BM was limited.

## Supplementary Figure S3



**Figure S3.  $^{89}\text{Zr}$ -oxine-labeled  $\text{CD34}^+$  HSPCs traffick to the BM.**

**A.** Axial PET/CT image of mid-4<sup>th</sup> lumbar spine 1 day after autologous transfer of  $^{89}\text{Zr}$ -oxine labeled  $\text{CD34}^+$  HPSCs showed high cell accumulation in the center of the vertebral body which is considered to be BM area. Note higher scale setting of the image compared to that of *ex vivo* expanded NK cells (Fig. 2B) because of very strong  $^{89}\text{Zr}$ -signals with  $\text{CD34}^+$  HPSCs. **B.** % ID curves demonstrated rapid migration of  $^{89}\text{Zr}$ -oxine-labeled HSPCs to the BM.